DE69533900D1 - Substituierte 6(4)-Benzyloxypyrimidine - Google Patents

Substituierte 6(4)-Benzyloxypyrimidine

Info

Publication number
DE69533900D1
DE69533900D1 DE69533900T DE69533900T DE69533900D1 DE 69533900 D1 DE69533900 D1 DE 69533900D1 DE 69533900 T DE69533900 T DE 69533900T DE 69533900 T DE69533900 T DE 69533900T DE 69533900 D1 DE69533900 D1 DE 69533900D1
Authority
DE
Germany
Prior art keywords
mammal
substituted
compounds
aza
guanine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69533900T
Other languages
English (en)
Other versions
DE69533900T2 (de
Inventor
C Moschel
E Pegg
M Dolan
Mi-Young Chae
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Arch Development Corp
Penn State Research Foundation
Original Assignee
US Department of Health and Human Services
Arch Development Corp
Penn State Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, Arch Development Corp, Penn State Research Foundation filed Critical US Department of Health and Human Services
Publication of DE69533900D1 publication Critical patent/DE69533900D1/de
Application granted granted Critical
Publication of DE69533900T2 publication Critical patent/DE69533900T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69533900T 1994-08-01 1995-07-31 Substituierte 6(4)-Benzyloxypyrimidine Expired - Fee Related DE69533900T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US283953 1994-08-01
US08/283,953 US5525606A (en) 1994-08-01 1994-08-01 Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines

Publications (2)

Publication Number Publication Date
DE69533900D1 true DE69533900D1 (de) 2005-02-03
DE69533900T2 DE69533900T2 (de) 2005-12-29

Family

ID=23088285

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69533900T Expired - Fee Related DE69533900T2 (de) 1994-08-01 1995-07-31 Substituierte 6(4)-Benzyloxypyrimidine
DE69523462T Expired - Fee Related DE69523462T2 (de) 1994-08-01 1995-07-31 Substituierte o6-benzylguanine

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69523462T Expired - Fee Related DE69523462T2 (de) 1994-08-01 1995-07-31 Substituierte o6-benzylguanine

Country Status (10)

Country Link
US (8) US5525606A (de)
EP (3) EP0775142B1 (de)
JP (2) JP3981407B2 (de)
AT (2) ATE207490T1 (de)
CA (2) CA2195856C (de)
DE (2) DE69533900T2 (de)
DK (2) DK1142893T3 (de)
ES (2) ES2233513T3 (de)
PT (2) PT775142E (de)
WO (1) WO1996004281A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6043228A (en) * 1993-06-08 2000-03-28 Cancer Research Campaign Technology Limited O6 -substituted guanine derivatives, a process for their preparation and their use in treating tumor cells
US5929046A (en) * 1994-06-08 1999-07-27 Cancer Research Campaign Technology Limited Pyrimidine and purine derivatives and their use in treating tumour cells
US5525606A (en) 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
US6794390B2 (en) * 1996-08-02 2004-09-21 Cv Therapeutics, Inc. Purine inhibitors of cyclin dependent kinase 2 & ikappabalpha
DE19653646A1 (de) * 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
DE69832715T2 (de) * 1997-07-12 2007-01-11 Cancer Research Technology Ltd. Cyclin-abhängige-kinase inhibierende purinderivate
US6060458A (en) * 1998-02-13 2000-05-09 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxyribonucleotides comprising O6 -benzylguanine and their use
GB9806739D0 (en) * 1998-03-28 1998-05-27 Univ Newcastle Ventures Ltd Cyclin dependent kinase inhibitors
US6677345B1 (en) * 1998-03-28 2004-01-13 Cancer Research Campaign Technology Limited Cyclin dependent kinase inhibitors
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
KR100368515B1 (ko) * 1999-02-03 2003-01-24 주식회사 엘지생명과학 싸이클린 의존 키나아제 저해제 및 그의 제조 방법
US8791081B2 (en) * 1999-08-13 2014-07-29 Case Western Reserve University MGMT inhibitor combination for the treatment of neoplastic disorders
US6376514B1 (en) 2000-10-17 2002-04-23 The Procter & Gamble Co. Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
WO2002036578A2 (en) * 2000-10-31 2002-05-10 Lynn Bonham Triazine derivatives as lpaat-b inhibitors and uses thereof
GB0101686D0 (en) * 2001-01-23 2001-03-07 Cancer Res Campaign Tech Cyclin dependent kinase inhibitors
BR0207302A (pt) * 2001-02-08 2004-02-10 Memory Pharm Corp Trifluorometilpurinas como inibidores da fosfodiesterase 4
US20030129186A1 (en) 2001-07-25 2003-07-10 Biomarin Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
JP4397691B2 (ja) * 2001-10-30 2010-01-13 コンフォーマ・セラピューティクス・コーポレイション Ｈｓｐ９０阻害活性を有するプリン類似体
US20070129334A1 (en) * 2001-10-30 2007-06-07 Conforma Therapeutics Corporation Orally Active Purine-Based Inhibitors of Heat Shock Protein 90
WO2004014913A2 (en) * 2002-08-08 2004-02-19 Memory Pharmaceuticals Corporation Derivatives of 2-trifluormethyl-6-aminopurine as phosphodiesterase 4 inhibitors
EP1551837A1 (de) * 2002-08-08 2005-07-13 Memory Pharmaceutical Corporation Phosphodiesterase-4-inhibitoren
GB0219746D0 (en) * 2002-08-23 2002-10-02 Inst Of Ex Botany Ascr Azapurine derivatives
DE10307928A1 (de) * 2003-02-25 2004-09-16 Faustus Forschungs Cie. Translational Cancer Research Gmbh Verwendung von 1-(2-Chlorethyl)-1-nitroso-3-(2-hydroxyethyl)-urea zur Behandlung von Pankreaskarzinomen, Weichteilsarkomen, Hodentumoren, Lymphomen, Thymomen, Wilms Tumoren, Nierenkarzinomen, Melanomen, Lungentumoren, intracerebralen Metastasen, Tumoren im Kopf- und Halsbereich, und Mamma-Karzinomen
US7138401B2 (en) * 2003-09-18 2006-11-21 Conforma Therapeutics Corporation 2-aminopurine analogs having HSP90-inhibiting activity
AU2004313931A1 (en) * 2004-01-06 2005-07-28 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services 2-amino-O4-substituted pteridines and their use as inactivators of O6-alkylguanine-DNA alkyltransferase
BRPI0511064A (pt) * 2004-05-12 2007-12-26 Bayer Cropscience Gmbh regulação de crescimento da planta
WO2006029065A1 (en) * 2004-09-08 2006-03-16 Goverment Of The United States Of America Represented By The Secretary, Department Of Health And Human Services Beta-gluguronidase cleavable prodrugs of o6-alkylguanine-dna alkyltransferase inactivators
US7825096B2 (en) * 2004-09-08 2010-11-02 The United States Of America As Represented By The Department Of Health And Human Services O6-alkylguanine-DNA alkyltransferase inactivators and beta-glucuronidase cleavable prodrugs
CN100386115C (zh) * 2004-10-14 2008-05-07 孔庆忠 一种抗癌药物组合物
GB0502573D0 (en) * 2005-02-08 2005-03-16 Topotarget As Therapeutic compounds
JP2008534609A (ja) 2005-03-30 2008-08-28 コンフォーマ・セラピューティクス・コーポレイション Ｈｓｐ９０阻害剤としてのアルキニルピロロピリミジンおよび関連類似体
EP1874738B1 (de) * 2005-04-27 2016-06-29 Covalys Biosciences AG Mit o6-alkylguanin-dna-alkyltransferase reagierende pyrimidine
PT1889198E (pt) 2005-04-28 2015-03-06 Proteus Digital Health Inc Sistema fármaco-informático
EP1931352B1 (de) 2005-08-22 2016-04-13 The Regents of The University of California Tlr-agonisten
WO2007035963A2 (en) * 2005-09-23 2007-03-29 Conforma Therapeutics Corporation Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors
EP2029597A4 (de) * 2006-05-31 2011-11-23 Univ California Purinanaloga
WO2008036682A2 (en) 2006-09-18 2008-03-27 Raptor Pharmaceutical Inc. Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
PL2510946T3 (pl) 2007-02-07 2015-12-31 Univ California Koniugaty syntetycznych agonistów tlr i ich zastosowania
US8188055B2 (en) * 2007-05-02 2012-05-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inactivators of O6-alkylguanine-DNA alkyltransferase
EP1990661B1 (de) 2007-05-07 2018-08-15 CSEM Centre Suisse d'Electronique et de Microtechnique SA - Recherche et Développement Isotroper Diffraktionsfilter nullter Ordnung
US20090202626A1 (en) * 2008-02-07 2009-08-13 Carson Dennis A Treatment of bladder diseases with a tlr7 activator
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
BRPI1008383A2 (pt) * 2009-02-11 2016-02-23 Univ California composto, composição farmacêutica, método para prevenir, inibir ou tratar uma condição, e, uso de um composto
PT2398500T (pt) 2009-02-20 2019-06-14 2 Bbb Medicines B V Sistema de entrega de medicamentos à base de glutationas
ES2942923T3 (es) 2009-05-06 2023-06-07 Laboratory Skin Care Inc Composiciones de administración dérmica que comprenden complejos de agente activo-partículas de fosfato de calcio y métodos de uso de las mismas
WO2011028507A2 (en) * 2009-08-24 2011-03-10 Duke University Compositions, methods, and kits for determining an alkyl transferase
CN101850504B (zh) * 2010-05-06 2011-11-16 陕西理工学院 一种用两个步进电机控制主轴运动的振动制孔装置
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
GB201106814D0 (en) * 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compounds
SG10201801668WA (en) 2011-06-10 2018-03-28 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
US20130236504A1 (en) * 2012-03-06 2013-09-12 Medical University Of South Carolina Delivery System for Enhancing Drug Efficacy
US9775835B2 (en) 2012-08-06 2017-10-03 Sirga Advanced Biopharma, Inc. Small molecule inhibitors of viral protein interactions with human t-RNA
EP3191486B1 (de) * 2014-09-11 2018-08-01 Bristol-Myers Squibb Company Thioethertriazolopyridin und triazolopyrmidininhibitoren von myeloperoxidase
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4199574A (en) * 1974-09-02 1980-04-22 Burroughs Wellcome Co. Methods and compositions for treating viral infections and guanine acyclic nucleosides
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
IL64501A (en) * 1980-12-22 1985-07-31 Astra Laekemedel Ab 9-substituted 4-hydroxybutyl guanine derivatives,their preparation and antiviral use
US5260291A (en) 1981-08-24 1993-11-09 Cancer Research Campaign Technology Limited Tetrazine derivatives
US5731304A (en) * 1982-08-23 1998-03-24 Cancer Research Campaign Technology Potentiation of temozolomide in human tumour cells
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
DE3485225D1 (de) * 1983-08-18 1991-12-05 Beecham Group Plc Antivirale guanin-derivate.
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4801710A (en) * 1984-10-26 1989-01-31 Merck & Co., Inc. Regioselective synthesis of 9-substituted purine acyclonucleoside derivatives
EP0184473A1 (de) * 1984-10-26 1986-06-11 Merck & Co. Inc. Regiospezifische Synthese von 9-substituierten Purinazyklonukleosidverbindungen
US4751221A (en) * 1985-10-18 1988-06-14 Sloan-Kettering Institute For Cancer Research 2-fluoro-arabinofuranosyl purine nucleosides
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4965270A (en) * 1987-05-30 1990-10-23 Beecham Group P.L.C. Purine derivatives
US5723609A (en) * 1988-03-30 1998-03-03 E. R. Squibb & Sons, Inc. Bis (hydroxymethyl) cyclobutyl purines
US5691307A (en) * 1990-03-13 1997-11-25 The United States Of America As Represented By The Department Of Health And Human Services O6 -substituted guanine compositions and methods for depleting O6
US5091430A (en) * 1990-03-13 1992-02-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services O6 -substituted guanine compounds and methods for depleting O6 -alkylguanine-DNA alkyltransferase levels
US5352669A (en) * 1990-03-13 1994-10-04 The Of The United States Of America As Represented By The Department Of Health And Human Services O6 -benzylated guanine, guanosine and 2'-deoxyguanosine compounds possessing O6 -alkylguanine-DNA alkyltransferase depleting activity
EP0489878A1 (de) * 1990-06-29 1992-06-17 Vinamul Ltd. Emulsionspolymerisation
FR2676058B1 (fr) 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
DE4236237A1 (de) 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
DE4311651A1 (de) * 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
JP4054057B2 (ja) 1993-06-08 2008-02-27 キャンサー・リサーチ・テクノロジー・リミテッド Ｏ▲上６▼−置換グアニン誘導体、それらの製造方法および腫瘍細胞の処置におけるそれらの使用
US6043228A (en) 1993-06-08 2000-03-28 Cancer Research Campaign Technology Limited O6 -substituted guanine derivatives, a process for their preparation and their use in treating tumor cells
EP0647450A1 (de) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Verbesserte Prodrogen für Enzym-vermittelten-Aktivierungen
DE69425356T2 (de) 1993-09-22 2002-04-18 Hoechst Ag Pro-Prodrugs, ihre Herstellung und Anwendung
US5929046A (en) 1994-06-08 1999-07-27 Cancer Research Campaign Technology Limited Pyrimidine and purine derivatives and their use in treating tumour cells
US5525606A (en) 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
ATE316799T1 (de) 1996-03-12 2006-02-15 Sanofi Aventis Deutschland Neuartige prodrugs für die therapie von tumoren und entzündlichen erkrankungen
US5965126A (en) 1996-03-25 1999-10-12 The Penn State Research Foundation use of mutant alkyltransferases for gene therapy to protect from toxicity of therapeutic alkylating agents
WO1999025386A1 (en) 1997-11-13 1999-05-27 Case Western Reserve University delta-O6-METHYLGUANINE-DNA METHYLTRANSFERASE GENE TRANSFER FOR O6-BENZYLGUANINE AND (N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA) RESISTANCE

Also Published As

Publication number Publication date
DK1142893T3 (da) 2005-03-29
ES2233513T3 (es) 2005-06-16
CA2195856A1 (en) 1996-02-15
US6172070B1 (en) 2001-01-09
PT1142893E (pt) 2005-04-29
CA2632452A1 (en) 1996-02-15
US6303604B1 (en) 2001-10-16
US6333331B1 (en) 2001-12-25
EP1142893B1 (de) 2004-12-29
US5525606A (en) 1996-06-11
US5958932A (en) 1999-09-28
DK0775142T3 (da) 2002-02-18
JPH10508288A (ja) 1998-08-18
EP0775142A1 (de) 1997-05-28
EP1142893A1 (de) 2001-10-10
EP0775142B1 (de) 2001-10-24
US5916894A (en) 1999-06-29
ATE286054T1 (de) 2005-01-15
US5753668A (en) 1998-05-19
PT775142E (pt) 2002-04-29
DE69523462T2 (de) 2002-07-11
AU3207995A (en) 1996-03-04
US20020013299A1 (en) 2002-01-31
ES2167451T3 (es) 2002-05-16
DE69533900T2 (de) 2005-12-29
CA2195856C (en) 2008-09-30
DE69523462D1 (de) 2001-11-29
EP1518854A1 (de) 2005-03-30
ATE207490T1 (de) 2001-11-15
JP3981407B2 (ja) 2007-09-26
US6436945B2 (en) 2002-08-20
WO1996004281A1 (en) 1996-02-15
JP2007077157A (ja) 2007-03-29
AU702711B2 (en) 1999-03-04

Similar Documents

Publication Publication Date Title
DE69533900D1 (de) Substituierte 6(4)-Benzyloxypyrimidine
BG103417A (en) Condensed pyrimidine bicyclic derivatives
FI930753A (fi) Nya fosfolipidderivat av nukleosider, deras framstaellning och deras anvaendning saosom antivirala laekemedel
SG54203A1 (en) Novel 7- (substituted)-8-(substituted)-9- [(substituted glycyl]-6-demethyl-6-deoxytetracyclines
PL300068A1 (en) 9-(substituted glycil) amido-6-demethyl-6-deoxytetracyclines, methods of obtaining such compounds as well as their organic and inorganic salts or metal complexes, pharmaceutical agent and veterinari agent
DK0582788T3 (da) 7-(Substituerede)-9-[(substitueret glycyl)-amido]-demethyl-6-deoxytetracycliner
EA200000592A1 (ru) Азаполициклические соединения, конденсированные с арилом
BR9805734A (pt) Derivados de imidazolin-4-ona úteis como agentes anticancerìgenos.
NO890567D0 (no) Anthracyklin-derivater.
ES2072881T3 (es) Procedimiento de preparacion de glicoconjugados de fosforamida mostaza e isofosforamida mostaza.
IL123776A0 (en) Novel derivatives of cyclodepsipeptide PF 1022
EA200100516A1 (ru) Производные 3,3-биарилпиперидина и 2,2-биарилморфолина
DE3028340C2 (de)
ES2134313T3 (es) Utilizacion de derivados de pregnano para el tratamiento de tumores.
ES2102772T3 (es) Compuesto citotoxico y antiviral.
GB8805642D0 (en) New cephem compounds & processes for preparation thereof
BR0000901A (pt) Derivados 4-fenil-4-heteroarilpiperidina
YU46302A (sh) Supstituisani piroli
KR970702869A (ko) 항종양성 인돌로피롤로카르바졸 유도체(antitumor indolopyprolocarbazole derivative)
AR042571A1 (es) L-arabino disacaridos de antraciclinas, sus procesos de preparacion y composiciones farmaceuticas que los contienen y su uso para la preparacion de composisiones farmaceuticas
DK0626383T3 (da) Palau'amin: Farmakologisk aktiv forbindelse fra en svamp
ECSP993220A (es) Derivados de 3,3- biarilpiperidina y 2,2 - biarilmorfolina

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee